Empfehlungen zur Anwendung von Thalidomid bei ... - DGHO

Konsensus Thalidomid, 19. Juli 2005, Seite 44 von 51 Seiten
40. Steurer M, Spizzo G, Mitterer M, Gastl G. Low-dose thalidomide for multiple
myeloma: interim analysis of a compassionate use program. Onkologie 2004;
27: 150-154.
41. Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK.
Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less
toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma
2003; 44: 1147-1149.
42. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma.
Blood 2004; 103: 20-32.
43. Oakervee HE, Gupta V, Smith ML, et al. Response to thalidomide can be
predicted by paraprotein quantitation 14 days after initiating therapy. Br J
Haematol 2001; 113(S1): 40 [abstract].
44. Loprinzi C, Rajkumar SV. Why not start with thalidomide? J Clin Oncol
2003; 21: 2211-2214.
45. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone
or with dexamethasone for previously untreated multiple myeloma. J Clin
Oncol 2003; 21: 16-19.
46. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously
untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15:
1274-1276.
47. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with
thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol
2002; 20: 4319-4323.
48. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and
dexamethasone in preparation for autologous stem cell transplantation for
multiple myeloma. Haematologica 2004; 89: 826-831.
49. Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing
melphalan-prednisone (MP), MP-thalidomide (MP-Thal) and high-dose
therapy using melphalan 100 mg/m² (MEL100) for newly diagnosed myeloma
patients aged 65-75 years. Interim analysis of the IFM 99-06 trial on 350
patients. Blood 2004; 104: abstract206 [abstract].
50. Goldschmidt H, Sonneveld P, Cremer FW, et al. Joint HOVON-50/GMMG-
HD3 randomized trial on the effect of thalidomide as part of a high-dose
therapy regimen and as maintenance treatment for newly diagnosed myeloma
patients. Ann Hematol 2003;
51. Lokhorst HM, Breitkreutz I, van der Holt B, et al. First interim analysis of the
Joint HOVON-50/GMMG-HD3 randomized study on the effect of thalidomide
combined with adriamycin, dexamethasone and high dose melphalan in
patients with multiple myeloma. Haematologica 2005; 90 (s1): 56 [abstract].